Table 2 Advanced disease lymphoblastic lymphoma in children

From: Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies

Cooperative Gp.

BFM 11

BFM 19

St Jude 23

EORTC-CLG 22

AIEOP 18

CCG 20

Patients (N)

101

335

41

121

55

85

Protocol

NHL-BFM-90

NHL-BFM-95

NHL13

CLG 58881

LNH-92

CCG 5941

Duration (months)

24

24

32

24

24

12

CRT

All patients

CNS+ only

None

None

CNS+ only

CNS+ only

CNS– dose

0 or 12 Gya

NA

None

None

NA

NA

CNS+ dose

0, 18, or 24 Gya

0, 12, or 18 Gyb

None

None

18 Gy

18 Gy

EFS (Est) 3-6 years

90%

84%

83%

78%

69%

78%

  1. Abbreviations: AIEOP, Italian Association of Pediatric Hematology and Oncology; BFM, Berlin–Frankfurt–Munster; EORTC-CLG, European Organization for Research and Treatment of Cancer-Children's Leukemia Group; CCG, Children's Cancer Group; CNS, central nervous system; CRT, cranial radiation therapy; EFS, event-free survival; Est, estimate; LNH, lymphoma non-Hodgkin; NA, not applicable; NHL, non-Hodgkin lymphoma.
  2. aOn BFM-90, children under 1 year received no CRT, CNS+ children 1–2 years received 18 Gy, and CNS+ children ⩾2 received 24 Gy.
  3. bOn BFM-95, children under 1 year received no CRT, CNS+ children 1–2 years received 12 Gy, and CNS+ children ⩾2 received 18 Gy.
  4. Reprinted from Cairo.5
Back to article page